Filing identity and reporting period
The supplied filing is Oculus Innovative Sciences, Inc.’s Form 10-Q, not a filing by Sonoma Pharmaceuticals, Inc. It reports the quarter ended June 30, 2013, the first quarter of Oculus’s fiscal year ending March 31, 2014. Financial statement amounts below are in U.S. dollars; dollar figures are in millions unless noted.
Financial performance and liquidity
| Metric | Quarter ended June 30, 2013 | Prior-year quarter |
|---|---|---|
| Revenue | $3.372 | $4.051 |
| Gross profit | $2.200; 65% of revenue | $2.884; 71% of revenue |
| Operating expenses | $3.326 | $3.379 |
| Operating loss | $(1.126) | $(0.495) |
| Net income (loss) | $(1.712) | $0.445 |
| Operating cash flow | $(1.057) | $(1.264) |
- Product revenue was $3.154 million, including $0.433 million in licensing fees; service revenue was $0.218 million. Product revenue fell 17% year over year.
- Cash and cash equivalents were $5.380 million at June 30, down $2.520 million from March 31. Investing cash outflow was $0.170 million and financing cash outflow was $1.257 million.
- Working capital was $4.191 million, versus $6.407 million at March 31. Total debt, net of discounts, was $1.353 million ($0.657 million current and $0.696 million long-term). The company paid $0.748 million of debt principal during the quarter.
- Total liabilities were $7.964 million, including $4.530 million of current and long-term deferred revenue. Stockholders’ equity was $2.617 million.
Material changes and unusual items
- U.S. product revenue declined $0.710 million, or 35%, primarily due to lower dermatology and animal-healthcare sales. Revenue from animal-healthcare partners fell to $0.741 million from $1.136 million; management attributed part of the decline to delayed seasonal demand after winter storms and expected future growth.
- Mexico revenue increased 3% to $1.424 million. Higher unit volume and $0.375 million of amortized More Pharma upfront fees were partly offset by lower average selling prices. Management said transferring the sales function to More Pharma reduced Mexican sales costs.
- Gross margin fell year over year, which management attributed mainly to lower margins associated with the More Pharma transaction. Licensing revenue rose to $0.433 million from $0.012 million.
- Net results included a $0.309 million non-cash fair-value loss on shares issued under the 2012 lender settlement arrangement. The company also recorded $0.167 million of non-cash interest expense.
- Effective April 1, 2013, Oculus completed a 1-for-7 reverse stock split; historical share and per-share data were retroactively adjusted.
Outlook, risks and contingencies
- Management expected cash to fund working-capital needs for sales, marketing and research and development through at least July 1, 2014, but anticipated continued losses and said additional capital may be needed. No new financing commitment had been secured; unavailable or unacceptable financing could require spending cuts, including to research and development.
- Management expected research and development and selling, general and administrative costs to increase as Ruthigen-related activities expanded. Pivotal U.S. clinical trials for Microcyn as a drug were expected to be delayed until a strategic funding partner was found.
- Ruthigen had filed a proposed IPO registration statement on August 8, 2013; the offering size and price range were undetermined and the registration statement was not yet effective. Related separation, licensing and services arrangements were contingent on the IPO closing. The filing describes potential milestone payments of $8 million and royalties of 3%–20% to Oculus, contingent on development, approval and sales milestones.
- Key risks include regulatory approval and clinical-development uncertainty, dependence on external financing, customer and distributor concentration, and execution of commercial partnerships. Two customers represented 42% and 22% of quarterly revenue. The company also disclosed a disputed Japan technology-license termination and a Mexico lawsuit; it had not accrued loss reserves for either matter.
- After quarter-end, the company approved a one-time $158,000 cash bonus for Ruthigen’s CEO related to the IPO filing and stated it would be its last bonus payment.
- The company reported no material change to previously disclosed annual-report risk factors, no defaults on senior securities, and no material change in internal control over financial reporting. Management concluded disclosure controls were effective at the reasonable-assurance level.
Important facts for investors to verify
- Confirm that this is the intended issuer and period: the filing is for Oculus Innovative Sciences, not Sonoma Pharmaceuticals.
- Assess cash runway against operating cash use, scheduled debt payments, and the company’s stated dependence on additional capital.
- Track whether U.S. revenue stabilizes and whether international growth and licensing revenue can offset the U.S. decline and weaker gross margin.
- Verify the status and terms of Ruthigen’s proposed IPO, reimbursement of Oculus’s offering costs, and any resulting cash or ongoing obligations.
- Review customer concentration, the More Pharma relationship and receivables, and developments in the disclosed litigation and license dispute.